Linkedin Labtau  

Michel Rivoire, MD, PhD, is Professor of Medicine in Surgical Oncology at the University Claude Bernard in Lyon, France, and Head of the Surgical Oncology Department at the Léon BÉRARD Cancer Center.

He was trained in Lyon and Paris University hospitals, and spent one year as a Research fellow in Memorial Sloan-Kettering Cancer in New York.

Dr. Rivoire obtained his medical degree in 1989 specializing in surgery from the University Claude Bernard in Lyon, France, and in 1995, he received his PhD, also from the University Claude Bernard, for his research on the use of radiolabelled monoclonal antibodies for diagnosis and treatment of liver metastases from colorectal cancer. He also holds a Master in Surgical Sciences “Cancérologie”, 1989, Paris XI.

Dr. Rivoire is an active member of a number of professional groups including the Society of Surgical Oncology, the European Society of Surgical Oncology, the Société Française de Chirurgie Oncologique, and the FondationFrançaise de Cancérologie Digestive. 

Dr. Rivoire has co-authored more than 162 peer-reviewed articles and over 105 abstracts and book chapters.

  1. Sphincter-saving surgery for ultra-low rectal carcinoma initially indicated for abdominoperineal resection: Is it safe on along-term follow-up?
    Rouanet P, Rivoire M, Gourgou S, Lelong B, Rullier E, Jafari M, Mineur L, Pocard M, Faucheron JL, Dravet F, Pezet D, Fabre JM, Bresler L, Balosso J, Taoum C,Lemanski C. J Surg Oncol. 2021 Jan;123(1):299-310. doi: 10.1002/jso.26249. Epub 2020 Oct 24.
  2. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomisedtrial.
    Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, de Chaisemartin C, Rivoire M, Trilling B, Jafari M, Portier G, Meunier B, Sieleznieff I, Bertrand M, Marchal F, Dubois A, Pocard M, Rullier A, Smith D, Frulio N, Frison E, Denost Q. Lancet Gastroenterol Hepatol. 2020 May;5(5):465-474. doi: 10.1016/S2468-1253(19)30410-8. Epub 2020 Feb 7.
  3. Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device forTreating Liver Metastases.
    Dupre A, Melodelima D, Perol D, Chen Y, Vincenot J, ChapelonJY, Rivoire M. J Vis Exp. 2019 Jan 9;(143). doi: 10.3791/57964.
  4. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
    Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, Faucheron JL, Jafari M, Portier G, Meunier B, Sileznieff I, Prudhomme M, Marchal F, Pocard M, Pezet D, Rullier A, Vendrely V, Denost Q, Asselineau J, Doussau A. Lancet. 2017 Jul 29;390(10093):469-479. doi: 10.1016/S0140-6736(17)31056-5. Epub 2017 Jun 7.
  5. Efficacy of high-intensity focused ultrasound-assisted hepatic resection (HIFU-AR) on blood loss reduction in patients with liver metastases requiring hepatectomy: study protocol for a randomized controlled trial.
    Dupré A, Pérol D, Blanc E, Peyrat P, Basso V, Chen Y, VincenotJ, Kocot A, Melodelima D, Rivoire M. Trials. 2017 Feb 6;18(1):57. doi: 10.1186/s13063-017-1801-2.
  6. Thermal Ablation of the Pancreas With Intraoperative High-Intensity Focused Ultrasound: Safety and Efficacy in a Porcine Model.
    Dupré A, Melodelima D, Pflieger H, Chen Y, Vincenot J, KocotA, Langonnet S, Rivoire M. Pancreas. 2017 Feb;46(2):219-224. doi: 10.1097/MPA.0000000000000720.